Non-SELEX method for aptamer selection against β-casomorphin-7 peptide

Parashar, Abhishek; Bhushan, Vanya; Mahanandia, Nimai Charan; Kumar, Sanjay; Mohanty, Ashok Kumar

doi:10.3168/jds.2021-21569

Cited by 8 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Centrifugation-based partitioning was developed for bacteria-specific aptamer selection by researchers from the Republic of Korea ( Kim et al, 2020 ). A research group from India used the bead-based non-SELEX method to generate an anti-beta-casomorphin-7 (BCM-7) peptide aptamer for the detection of BCM-7 in a human urine sample ( Parashar et al, 2022 ).…”

Section: Non-systematic Evolution Of Ligands By Exponential Enrichmen...mentioning

confidence: 99%

Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers

Zhao

Xue

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Aptamers are short single-strand oligonucleotides that can form secondary and tertiary structures, fitting targets with high affinity and specificity. They are so-called “chemical antibodies” and can target specific biomarkers in both diagnostic and therapeutic applications. Systematic evolution of ligands by exponential enrichment (SELEX) is usually used for the enrichment and selection of aptamers, and the targets could be metal ions, small molecules, nucleotides, proteins, cells, or even tissues or organs. Due to the high specificity and distinctive binding affinity of aptamers, aptamer–drug conjugates (ApDCs) have demonstrated their potential role in drug delivery for cancer-targeting therapies. Compared with antibodies which are produced by a cell-based bioreactor, aptamers are chemically synthesized molecules that can be easily conjugated to drugs and modified; however, the conventional ApDCs conjugate the aptamer with an active drug using a linker which may add more concerns to the stability of the ApDC, the drug-releasing efficiency, and the drug-loading capacity. The function of aptamer in conventional ApDC is just as a targeting moiety which could not fully perform the advantages of aptamers. To address these drawbacks, scientists have started using active nucleotide analogs as the cargoes of ApDCs, such as clofarabine, ara-guanosine, gemcitabine, and floxuridine, to replace all or part of the natural nucleotides in aptamer sequences. In turn, these new types of ApDCs, aptamer nucleotide analog drug conjugates, show the strength for targeting efficacy but avoid the complex drug linker designation and improve the synthetic efficiency. More importantly, these classic nucleotide analog drugs have been used for many years, and aptamer nucleotide analog drug conjugates would not increase any unknown druggability risk but improve the target tumor accumulation. In this review, we mainly summarized aptamer-conjugated nucleotide analog drugs in cancer-targeting therapies.

show abstract

Section: Non-systematic Evolution Of Ligands By Exponential Enrichmen...mentioning

confidence: 99%

Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers

Zhao

Xue

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…To select specific aptamers for high-affinity target molecules, 6-20 rounds of the SELEX procedure are often necessary. 43 Figure 6 sums up the SELEX procedure.…”

Section: Selection Of Aptamers By Systematic Evolution Of Ligands By ...mentioning

confidence: 99%

Application and Immunogenicity of Aptamers in Cancer Therapy

Ghazizadeh,

Amazadeh,

Ziyamolki

et al. 2023

Biomed Res Bull

View full text Add to dashboard Cite

Aptamers are short single-stranded nucleic acid (DNA or RNA) or peptide sequences with a unique three-dimensional structure that bind to their targets with high specificity and affinity. Aptamers’ small size, fast and cheap production process, low immunogenicity, and high stability have made them attractive molecules in some fields of research, especially in the design of new diagnostic and therapeutic pathways. This review article discusses aptamers’ applications and immunogenic properties in the pharmaceutical sciences.

show abstract

“…After amplification, the PCR-produced DNA is used as a template for RNA transcription, and this RNA aptamer pool would be put into the next round of SELEX. Except for the SELEX technique, the non-SELEX method is also developed for aptamer generation and mainly represents the no aptamer amplification involved in the selection [ 27 ]. The equilibrium capillary electrophoresis technology is utilized to separate the target-aptamer complex from the free DNA/RNA in the non-equilibrium capillary electrophoresis of equilibrium mixtures (NECEEM) [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

The application of Aptamer in biomarker discovery

Tam

et al. 2023

Biomark Res

View full text Add to dashboard Cite

Biomarkers are detectable molecules that can reflect specific physiological states of cells, organs, and organisms and therefore be regarded as indicators for specific diseases. And the discovery of biomarkers plays an essential role in cancer management from the initial diagnosis to the final treatment regime. Practically, reliable clinical biomarkers are still limited, restricted by the suboptimal methods in biomarker discovery. Nucleic acid aptamers nowadays could be used as a powerful tool in the discovery of protein biomarkers. Nucleic acid aptamers are single-strand oligonucleotides that can specifically bind to various targets with high affinity. As artificial ssDNA or RNA, aptamers possess unique advantages compared to conventional antibodies. They can be flexible in design, low immunogenicity, relative chemical/thermos stability, as well as modifying convenience. Several SELEX (Systematic Evolution of Ligands by Exponential Enrichment) based methods have been generated recently to construct aptamers for discovering new biomarkers in different cell locations. Secretome SELEX-based aptamers selection can facilitate the identification of secreted protein biomarkers. The aptamers developed by cell-SELEX can be used to unveil those biomarkers presented on the cell surface. The aptamers from tissue-SELEX could target intracellular biomarkers. And as a multiplexed protein biomarker detection technology, aptamer-based SOMAScan can analyze thousands of proteins in a single run. In this review, we will introduce the principle and workflow of variations of SELEX-based methods, including secretome SELEX, ADAPT, Cell-SELEX and tissue SELEX. Another powerful proteome analyzing tool, SOMAScan, will also be covered. In the second half of this review, how these methods accelerate biomarker discovery in various diseases, including cardiovascular diseases, cancer and neurodegenerative diseases, will be discussed.

show abstract

Non-SELEX method for aptamer selection against β-casomorphin-7 peptide

Cited by 8 publications

References 13 publications

Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers

Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers

Application and Immunogenicity of Aptamers in Cancer Therapy

The application of Aptamer in biomarker discovery

Contact Info

Product

Resources

About